Find More Contacts for Cellerant Therapeutics
Protected Content
CEO, President
Executive Management
1 email found 1 phone number found
View contacts for Cellerant Therapeutics to access new leads and connect with decision-makers.
View All Contacts
  • Company Type For Profit
  • Contact Email info@cellerant.com
  • Phone Number (650)232-2122

Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s Romyelocel-L is a universal cell therapy that does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia.

It was

founded in 2003 and headquartered in San Carlos, California.

Lists Featuring This Company

West Coast Clinical Trials Companies
588 Number of Organizations • $10B Total Funding Amount • 636 Number of Investors
United States Companies With More Than $10M in Revenue (Top 10K)
10,000 Number of Organizations • $3.1T Total Funding Amount • 66,132 Number of Investors
Western US Companies With Less Than $1B in Revenue (Top 10K)
9,892 Number of Organizations • $1.1T Total Funding Amount • 86,351 Number of Investors
California Companies With More Than 10 Employees (Top 10K)
9,966 Number of Organizations • $1.4T Total Funding Amount • 83,479 Number of Investors

Frequently Asked Questions

Where is Cellerant Therapeutics's headquarters? Cellerant Therapeutics is located in San Carlos, California, United States.Who invested in Cellerant Therapeutics? Cellerant Therapeutics has 7 investors including Camelot Collectables and Allen & Company.How much funding has Cellerant Therapeutics raised to date? Cellerant Therapeutics has raised .When was the last funding round for Cellerant Therapeutics? Cellerant Therapeutics closed its last funding round on Sep 26, 2016 from a Grant round.Who are Cellerant Therapeutics's competitors? Alternatives and possible competitors to Cellerant Therapeutics may include argenxAclaris Therapeutics, and Proteostasis Therapeutics.